80028783: Johns Hopkins Schizophrenia Center Annual Symposium

Accreditation Statement The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement The Johns Hopkins University School of Medicine designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Credit American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 35.25 hours of Category 1 credit for completing this program.

Course Description

Our symposium brings together world-renowned experts in schizophrenia whose areas of expertise are diverse yet complementary. A key pathology of schizophrenia is likely associated with the cerebral cortex. To gain a better understanding of disease development, the study of brain structure and function is the basis of schizophrenia research. This symposium addresses the educational needs of a wide range of audiences who are interested in, or working on schizophrenia and related disorders. By participating in this comprehensive and stimulating day of lectures, our audience will be able to learn how integrative science from (lab) bench to bedside, and eventually to society, is currently taking place at Hopkins and around the world.

Objectives

After attending this activity, the participant will demonstrate the ability to:

• Recognize how diagnostic criteria for psychotic disorders, including schizophrenia, have been established historically, and how criteria will be further formulated
• Identify how cognitive deficits and other clinical sub-symptoms of schizophrenia and related disorders are measured, and how essential such measurements are in bridging basic science and animal models, to clinical ascertainment and drug discovery
• Recognize the basic principles of how the brain, specifically the cerebral cortex, develops, and how the disturbance of such neurodevelopmental processes can underlie the risks of schizophrenia and related disorders
• Identify what types of pathological changes occur in brains of patients with schizophrenia and related disorders, and how such discoveries can lead to a mechanistic understanding of the pathology of the disease, and potentially lead to drug discovery strategies
• Discuss how cutting-edge neuroscience and biological approaches, including stem cell approaches, next generation sequencing, brain imaging, and computational modeling, will contribute to a better understanding of disease mechanisms and novel drug discoveries
• Discuss how such scientific advances can be promptly translated and delivered to clinical settings and society all over the world

Talks

Policy On Speaker And Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.